Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 4/20 | 0.46 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.46 |
| ▸ | HRH2 | P25021 | 1/20 | 0.46 |
| ▸ | HRH1 | P35367 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | DUT | P33316 | 2/20 | 0.37 |
| ▸ | GABRR1 | P24046 | 1/20 | 0.37 |
| ▸ | FDPS | P14324 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | F2 | P00734 | 1/20 | 0.33 |
| ▸ | HTR3A | P46098 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6740861 | 0.89 | HRH4 (0.50) | HRH4HRH3HRH2HRH1TDP1 | |
| SCHEMBL2830017 | 0.80 | HRH2 (0.44) | HRH4HRH3HRH2HRH1TDP1 | |
| SCHEMBL6743429 | 0.78 | DUT (0.36) | HRH3DUT | |
| SCHEMBL6741974 | 0.77 | DUT (0.36) | HRH3DUT | |
| SCHEMBL6741580 | 0.74 | KDM4E (0.42) | HRH4HRH3DUTHTR3A | |
| SCHEMBL8063404 | 0.71 | DUT (0.43) | DUT | |
| SCHEMBL10855808 | 0.71 | HRH1 (0.75) | HRH4HRH3HRH2HRH1TDP1 | |
| SCHEMBL13263780 | 0.70 | HRH3 (0.62) | HRH4HRH3HRH2HRH1TDP1 | |
| SCHEMBL11545778 | 0.69 | HRH1 (0.72) | HRH4HRH3HRH2HRH1TDP1 | |
| Hydrochloric Acid SCHEMBL11543895 | 0.69 | TDP1 (0.76) | HRH4HRH3HRH2HRH1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1446385-A1 | PREPARATION AND USE OF SUBSTITUTED IMIDAZOLES | NOVO NORDISK A/S (DK) | 2004-08-18 | — | — | EP | disclosed |
| US-20040127718-A1 | Substituted imidazoles | NOVO NORDISK A/S (DK) | 2004-07-01 | — | — | US | disclosed |
| US-20030181479-A1 | Substituted imidazoles | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2003-09-25 | — | — | US | disclosed |
| WO-2003040106-A1 | PREPARATION AND USE OF SUBSTITUTED IMIDAZOLES | NOVO NORDISK A/S (DK) | 2003-05-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030181479-A1 | Substituted imidazoles | HRH3, HRH4, HRH2 | HRH4 2/4885HRH3 1/4885HRH2 3/4885 |
| US-20040127718-A1 | Substituted imidazoles | HRH3, HRH4, HRH2 | HRH4 2/4885HRH3 1/4885HRH2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.